InvestSMART

Cogstate Limited (ASX:CGS)

ALERT: Price-sensitive ASX Announcement for CGS
Current share price for CGS : $2.710 -0.09 (-3.21%)+
Announcement
Release
8 Jul 2026 8:25AM
Price at Release
$2.800
Full Release
download
Summary
Cogstate Limited, a global leader in neuroscience endpoint innovation, reported its financial performance for the fourth quarter and full fiscal year ending June 30, 2026. The company achieved record net sales contracts totaling $89.0 million for FY26, marking a 116% increase from the previous year. For the upcoming fiscal year, Cogstate anticipates recognizing $48.3 million of its contracted future revenue, amounting to a 54% increase from last year's projections. Contracted clinical trials revenue for FY27 is expected to reach $46.1 million, a 58% increase from FY26. The company plans to release its audited FY26 Annual Report and host an investor call on August 18, 2026, to discuss detailed results and FY27 priorities.
Key Points
  • Record net sales contracts of $89.0 million in FY26, up 116% from FY25.
  • $48.3 million of future revenue expected for FY27, up 54%.
  • $46.1 million projected clinical trials revenue for FY27, a 58% increase.
  • Cogstate specializes in CNS measurement for accurate clinical trial data.
  • FY26 Annual Report to be released on August 18, 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.